PIK3R1 mutation associated with primary immunodeficiency: a case of a 14-year-old male and review of the literature: case report

Enas S. Alharbi, Talal Saleh Alzahrani, Manal Mohammed Afqi, Ayman Elhomoudi
{"title":"PIK3R1 mutation associated with primary immunodeficiency: a case of a 14-year-old male and review of the literature: case report","authors":"Enas S. Alharbi, Talal Saleh Alzahrani, Manal Mohammed Afqi, Ayman Elhomoudi","doi":"10.15406/jpnc.2023.13.00485","DOIUrl":null,"url":null,"abstract":"We report a rare case of a 14-year-old boy diagnosed with Activated phosphoinositide 3-kinase delta syndrome Type 2 (APDS2). Based on a typical clinical presentation (Delayed teething, Prominent lymphadenopathy and recurrent characteristic infections started early in life and including multiple episodes of bilateral conjunctivitis, an extensive herpes skin infection in addition to recurrent upper sinopulmonary infections) along with suggestive laboratory immunological findings, and positive confirmatory genetic testing. After diagnosis, the patient was commenced on prophylactic antibiotics which resulted in a reduction in the frequency of his infections and hospitalizations. The targeted therapy of mTOR inhibition with Sirolimus and the possibility of hematopoietic stem cells transplantation are considered and discussed with the family, and he is on regular follow-up with the Allergy/Immunology team. APDS is a rare but increasingly reported inborn error of immunity. Gain-of-function and loss-of-function mutations in phosphoinositide 3-kinase (PIK3CD (encoding P 110 δ ) and PIK3R1 (encoding p 85 α , p 55 α , a n d p 50 α )) lead to APDS1 and APDS2, respectively. Our aim in reporting our case is to allow room for more elaboration of the different genotypes and clinical presentations of both types of APDS, in which early and accurate diagnosis will subsequently help in the initiation of outcome-improving therapy.","PeriodicalId":388959,"journal":{"name":"Journal of Pediatrics & Neonatal Care","volume":"41 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pediatrics & Neonatal Care","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/jpnc.2023.13.00485","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

We report a rare case of a 14-year-old boy diagnosed with Activated phosphoinositide 3-kinase delta syndrome Type 2 (APDS2). Based on a typical clinical presentation (Delayed teething, Prominent lymphadenopathy and recurrent characteristic infections started early in life and including multiple episodes of bilateral conjunctivitis, an extensive herpes skin infection in addition to recurrent upper sinopulmonary infections) along with suggestive laboratory immunological findings, and positive confirmatory genetic testing. After diagnosis, the patient was commenced on prophylactic antibiotics which resulted in a reduction in the frequency of his infections and hospitalizations. The targeted therapy of mTOR inhibition with Sirolimus and the possibility of hematopoietic stem cells transplantation are considered and discussed with the family, and he is on regular follow-up with the Allergy/Immunology team. APDS is a rare but increasingly reported inborn error of immunity. Gain-of-function and loss-of-function mutations in phosphoinositide 3-kinase (PIK3CD (encoding P 110 δ ) and PIK3R1 (encoding p 85 α , p 55 α , a n d p 50 α )) lead to APDS1 and APDS2, respectively. Our aim in reporting our case is to allow room for more elaboration of the different genotypes and clinical presentations of both types of APDS, in which early and accurate diagnosis will subsequently help in the initiation of outcome-improving therapy.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
PIK3R1突变与原发性免疫缺陷相关:一名14岁男性病例及文献回顾:病例报告
我们报告一例罕见的14岁男孩被诊断为活化磷酸肌肽3-激酶δ综合征2型(APDS2)。基于一个典型的临床表现(延迟出牙,突出的淋巴结病和复发性特征性感染开始于生命早期,包括多次发作的双侧结膜炎,广泛的疱疹皮肤感染以及复发性上肺感染),以及暗示性的实验室免疫学结果,以及阳性的确诊基因检测。诊断后,患者开始使用预防性抗生素,从而减少了感染和住院的频率。考虑并与家人讨论了西罗莫司靶向治疗mTOR抑制和造血干细胞移植的可能性,并与过敏/免疫学团队定期随访。APDS是一种罕见但越来越多报道的先天性免疫错误。磷酸肌肽3激酶(PIK3CD(编码p110 δ)和PIK3R1(编码p85 α、p55 α、an和p50 α)的功能获得和功能丧失突变分别导致APDS1和APDS2。我们报告这一病例的目的是为两种APDS的不同基因型和临床表现提供更多的阐述空间,在这种情况下,早期和准确的诊断将有助于随后开始改善结果的治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The primary nutritional approach in pediatric celiac disease: a mini-review Prevalence and associated factor of neonatal mortality among neonates admitted to Asella referral and teaching hospital, Asella, Ethiopia, 2024 Efficacy and safety of Pranabb® syrup to reduce cough and improve sleep quality in children compared to usual recommended hydration measures Neonatal acidity and pyloric stenosis of infancy (PS) - the beginning and the end two stories PATAU SYNDROME- An Unusual Case of Congenital Abnormality
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1